Skip Navigation LinksHome > Professional Development > eLearning > Development and Use of a Universal Transfusion Adverse Event Form

Development and Use of a Universal Transfusion Adverse Event Form

Please note: AABB reserves the right to make updates to this program.

Tuesday, December 4, 2018 - [Rescheduled from 06/12/18]
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 18EL-338 (see program format numbers below under Registration)

Educational Track: Technical/Clinical
Topic: Transfusion Medicine (Hemovigilance)
Intended Audience: Hospital Blood Banks, Medical Directors, Nurses, Physicians
Teaching Level: Intermediate

Moderator: Deanna Fang, Director Blood Bank, Mayo Clinic, Jacksonville, FL
Speakers: Mark Fung, MD, PhD, Director of Clinical Laboratories, University of Vermont Medical Center, Burlington, VT; Kevin Land, MD, Vice President, Clinical Services, Blood Systems Inc., Fair Oaks, TX; Mary Townsend, MD, Senior Medical Director, Blood System Inc., Scottsdale, AZ

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Describe the types of TARs that should be reported to blood collecting organizations.
  • Identify key types of information needed to evaluate hospital reported TARs.
  • Describe the outcome of hospital trials using the new universal TAR Reporting Form.

Program Description

Reporting to the blood collection establishment (BCE) of Transfusion Adverse Reactions (TARs) thought to be due to an attribute specific to the donor or the processing of the blood product is necessary to enable the BCE to take action on co-components and manage donor eligibility. Accuracy of reporting may be expedited through the use of a user-friendly form. Such a form has been developed by the AABB Hemovigilance Committee. This program will describe the development of this form and present results from early trials in participating hospitals and BCE.


   Program #
Single Viewer: Live Register18EL-338-2032
Single Viewer: On-Demand Register18EL-338-4032
Group Viewing: Live Register18EL-338-6032
Group Viewing: On-Demand Register18EL-338-8032
Group Viewing: Live & On-Demand Register18EL-338-9932

Speaker Biographies

Dr. Mark Fung is professor of pathology and laboratory medicine at the University of Vermont, and is vice chair of quality and clinical affairs for Pathology and Laboratory Medicine at the University of Vermont Health Network, and director of clinical laboratories at University of Vermont Medical Center.  Dr. Fung has served in a number of leadership capacities within the AABB and other related organizations.  These activities include the development of multiple transfusion guidelines and the implementation of transfusion reaction reporting using standardized definitions.  He is the editor-in-chief for the 18th and upcoming 19th editions of the AABB Technical Manual.

Dr. Kevin Land serves as the Vice President of Clinical Services for Blood Systems - which includes oversight of Blood Systems Laboratory, therapeutic apheresis and cellular therapy services, and hospital-facing physicians.  He is also the Chief Medical Officer for the Blood Services Division in North Dakota, South Dakota, Wyoming, and Montana. He is a Clinical Informaticist and patient-oriented Transfusion Medicine physician who has focused much of his career on systems design and process improvement to improve donor and patient safety.  A Texas native, Dr. Land earned his bachelor’s degree in Biochemistry in 1990 from the University of North Texas and completed his medical degree and residency in Pathology at UT Southwestern in Dallas. After serving as chief resident, he completed fellowships in medical informatics at Johns Hopkins and transfusion medicine at Parkland Memorial Hospital.

Dr. Mary Townsend serves as the Senior Medical Director, Corporate at Blood Systems in Scottsdale.  Prior to joining BSI in September 2010, she served as the Vice President of Coffee Memorial Blood Center in Amarillo Texas for 24 years, where she is on clinical faculty of the Department of Internal Medicine of Texas Tech University Medical School. Dr. Townsend earned her bachelor’s degree in Chemistry and her master’s degree in Physical Chemistry prior to attending medical school at UT Southwestern in Dallas, TX.  She trained in Obstetrics and Gynecology at the University of Pennsylvania and completed her residency in Clinical Pathology at the Medical College of Pennsylvania.

Mary has spent her career focusing on the care and feeding of donors, for whom she has an abiding passion.  She was an inaugural member of the AABB Task Force to redesign the uniform donor questionnaire, serving as its second chair.  She chaired both the America’s Blood Centers’ Scientific, Medical, Technical and Quality committee and the ABC Donor Adverse Event committee.  She has been a member of the AABB Donor Biovigilance Working Group since its inception and was one of three centers to pilot the DonorHart Biovigilance system. She has been an editor of Notify Library since 2015, focusing on donor adverse events and infectious events in recipients.​